

Epstein-Barr Virus (EBV) gH/gL/gp42-Ferritin Nanoparticle Vaccine With or Without gp350-Ferritin in Healthy Adults With or Without EBV Infection

NCT06908096

Status	RECRUITING
Phase	Phase 1
Sponsor	National Institute of Allergy and Infectious Diseases (NIAID)
Enrollment	750 participants

Key Eligibility Criteria

Inclusion (28)

- To be eligible to participate in this study, an individual must meet all of the following criteria:
 - to 29 years old.
 - Able to provide informed consent.
 - Willingness to allow storage of blood and saliva for future research.
 - In good general health as evidenced by medical history, physical examination, and laboratory screening results.
- ... and 23 more (see full listing online)

Exclusion (28)

- An individual who meets any of the following criteria will be excluded from participation in this study:
 - Pregnant, breastfeeding, or planning to become pregnant while participating through 60 days after the last dose of vaccine.
 - Participant has received any of the following:
 - More than 10 days of systemic immunosuppressive medications (≥ 10 mg prednisone dose or its equivalent) or cytotoxic medication within the 30 days prior to first dose of vaccine or immunomodulating therapy within 180 days prior to first dose of vaccine.
 - Blood products, including immunoglobulin products, within 120 days prior to first dose of vaccine.
- ... and 23 more (see full listing online)

Locations (1 total)

National Institutes of Health Clinical Center, Bethesda, Maryland, United States